Kingsley Biotech (01548) plans to place 77.126 million shares at a discount of approximately 4.7% to raise approximately HK$2,327 billion

Zhitong Finance App News, Kingsley Biotechnology (01548) issued an announcement. On September 11, 2026, the company signed a placement agreement with the placement agent. Based on this, the Company agreed to appoint a placement agent and the placement agent conditionally agreed to do its best to induce a total of no less than six undertakers to subscribe for 77.126 million shares for the placement price of HK$30.50 per share in accordance with the terms and conditions set out in the placement agreement. It is anticipated that the placed shares will be placed to no less than 6 undertakers. It is anticipated that none of the assignees will become major shareholders immediately following the completion of the placement.

The placement price was HK$30.50 per share, compared to: (i) the shares were discounted by approximately 4.7% from the closing price of HK$32.00 per share on September 10, 2026 (the last trading day); and (ii) about 6.3% off the average closing price of HK$32.56 per share on the last five consecutive trading days immediately prior to the date of the placement agreement.

Placed shares account for (i) approximately 3.50% of the Company's issued share capital at the date of this announcement; and (ii) approximately 3.38% of the Company's issued share capital after being expanded through allotment and issuance of placed shares (assuming there is no change in the issued share capital of the Company from the date of this announcement to the date of delivery).

Assuming that all of the placed shares are placed, the total proceeds from the placement are estimated to be approximately HK$2.352 billion, and the net proceeds from the placement (net of placement commissions and other related expenses, including professional expenses) are estimated to be approximately HK$2,327 billion, which is equivalent to an estimated net issue price of approximately HK$30.17 per share.

The Company currently plans to use the net proceeds from the placement for the following purposes: (i) approximately 70% to expand the production capacity and infrastructure of the Group's AIDD platform, including automated high-throughput wet laboratory facilities, related equipment and laboratory upgrades; (ii) approximately 20% for R&D, digital workflow integration and global business expansion related to the AIDD platform; and (iii) approximately 10% for general corporate purposes and working capital. The specific use of proceeds may be adjusted by the board of directors or its authorized persons according to the operating conditions and actual needs of the Company or the Group.